Héroux-Devtek Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Héroux-Devtek heeft een totaal eigen vermogen van CA$469.2M en een totale schuld van CA$125.5M, wat de schuld-eigenvermogensverhouding op 26.7% brengt. De totale activa en totale passiva bedragen respectievelijk CA$959.7M en CA$490.5M. De EBIT Héroux-Devtek is CA$79.9M waardoor de rentedekking 5.4 is. Het heeft contanten en kortetermijnbeleggingen van CA$1.2M.

Belangrijke informatie

26.7%

Verhouding schuld/eigen vermogen

CA$125.50m

Schuld

Rente dekkingsratio	5.4x
Contant	CA$1.15m
Aandelen	CA$469.22m
Totaal verplichtingen	CA$490.47m
Totaal activa	CA$959.69m

Recente financiële gezondheidsupdates

Is Héroux-Devtek (TSE:HRX) Using Too Much Debt?

Apr 03

Recent updates

Héroux-Devtek Inc. (TSE:HRX) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected

Jun 08

Investors Shouldn't Be Too Comfortable With Héroux-Devtek's (TSE:HRX) Earnings

May 29

What Is Héroux-Devtek Inc.'s (TSE:HRX) Share Price Doing?

May 23

Results: Héroux-Devtek Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Feb 10

Results: Héroux-Devtek Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Nov 18

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( CA$544.5M ) HRX } overtreffen de korte termijn passiva ( CA$255.1M ).

Langlopende schulden: De kortetermijnactiva HRX ( CA$544.5M ) overtreffen de langetermijnschulden ( CA$235.4M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 26.5% ) HRX wordt als voldoende beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van HRX is de afgelopen 5 jaar gedaald van 58.9% naar 26.7%.

Schuldendekking: De schuld van HRX wordt goed gedekt door de operationele kasstroom ( 35.7% ).

Rentedekking: De rentebetalingen op de schuld van HRX worden goed gedekt door EBIT ( 5.4 x dekking).

Héroux-Devtek Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Héroux-Devtek Expects to Delist from TSX

Is Héroux-Devtek (TSE:HRX) Using Too Much Debt?

Recent updates

Héroux-Devtek Expects to Delist from TSX

Consensus EPS estimates increase by 17%

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improves as stock rises 23%

Platinum Equity, LLC, Gilles Labbé, Martin Brassard entered into an arrangement agreement to acquire Héroux-Devtek Inc. (TSX: HRX) from Caisse de dépôt et placement du Québec, Gilles Labbé, Martin Brassard and others in an equity reinvestment transaction for CAD 1.1 billion.

Héroux-Devtek Inc. (TSE:HRX) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected

Investors Shouldn't Be Too Comfortable With Héroux-Devtek's (TSE:HRX) Earnings

Consensus EPS estimates increase by 21%

Full year 2024 earnings: EPS and revenues exceed analyst expectations

What Is Héroux-Devtek Inc.'s (TSE:HRX) Share Price Doing?

Héroux-Devtek Inc., Annual General Meeting, Aug 06, 2024

Héroux-Devtek Inc. to Report Q4, 2024 Results on May 22, 2024

Price target increased by 7.5% to CA$24.50

Results: Héroux-Devtek Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Is Now The Time To Look At Buying Héroux-Devtek Inc. (TSE:HRX)?

Consensus EPS estimates increase by 26%

Price target increased by 7.3% to CA$20.70

Héroux-Devtek Inc. to Report Q3, 2024 Results on Feb 07, 2024

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Héroux-Devtek Inc. to Report Q2, 2024 Results on Nov 10, 2023

New major risk - Financial position

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Now 20% undervalued

Héroux-Devtek Inc., Annual General Meeting, Aug 08, 2023

Now 20% undervalued

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 40%

Third quarter 2023 earnings: Revenues in line with analyst expectations

Consensus EPS estimates fall by 42%

At CA$16.20, Is Héroux-Devtek Inc. (TSE:HRX) Worth Looking At Closely?

Investor sentiment improves as stock rises 16%

Héroux-Devtek Inc. to Report Q3, 2023 Results on Feb 08, 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Héroux-Devtek Inc. to Report Q2, 2023 Results on Nov 11, 2022

Consensus EPS estimates fall by 28%

Price target decreased to CA$21.80

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Héroux-Devtek Inc. to Report Q1, 2023 Results on Aug 05, 2022

Insider exercised options to buy CA$74k worth of stock.

CFO & VP recently sold CA$383k worth of stock

Héroux-Devtek Inc., Annual General Meeting, Aug 05, 2022

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 13%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Now 23% undervalued after recent price drop

President exercised options to buy CA$568k worth of stock.

Second quarter 2022 earnings released: EPS CA$0.21 (vs CA$0.11 in 2Q 2021)

Executive Chairman of the Board exercised options to buy CA$325k worth of stock.

First quarter 2022 earnings released: EPS CA$0.19 (vs CA$0.038 loss in 1Q 2021)

President exercised options to buy CA$188k worth of stock.

Is It Time To Consider Buying Héroux-Devtek Inc. (TSE:HRX)?

We Like Héroux-Devtek's (TSE:HRX) Earnings For More Than Just Statutory Profit

Full year 2021 earnings released: EPS CA$0.55 (vs CA$1.38 loss in FY 2020)

Price target increased to CA$22.00

Calculating The Fair Value Of Héroux-Devtek Inc. (TSE:HRX)

Is Héroux-Devtek (TSE:HRX) Using Too Much Debt?

New 90-day high: CA$16.46

Our Take On The Returns On Capital At Héroux-Devtek (TSE:HRX)

This Insider Has Just Sold Shares In Héroux-Devtek Inc. (TSE:HRX)

Héroux-Devtek Inc. Appoints Didier Evrard as Director

Third quarter 2021 earnings released: EPS CA$0.24 (vs CA$0.24 in 3Q 2020)

Revenue and earnings beat expectations

Price target raised to CA$18.83

New 90-day high: CA$15.40

Is There Now An Opportunity In Héroux-Devtek Inc. (TSE:HRX)?

A Look At The Intrinsic Value Of Héroux-Devtek Inc. (TSE:HRX)

Héroux-Devtek Inc. to Report Q3, 2021 Results on Feb 05, 2021

New 90-day high: CA$14.94

A Look At Héroux-Devtek's (TSE:HRX) Share Price Returns

What You Need To Know About Héroux-Devtek Inc.'s (TSE:HRX) Investor Composition

How Much Are Héroux-Devtek Inc. (TSE:HRX) Insiders Spending On Buying Shares?